{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:49:13Z","timestamp":1792054153184,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.psychres.2026.117299","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:07:56Z","timestamp":1781737676000},"page":"117299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term antipsychotic use and cardiometabolic adverse effects in adults with non-psychotic disorders: A systematic review"],"prefix":"10.1016","volume":"364","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-5919","authenticated-orcid":false,"given":"Ramya Padmavathy","family":"Radha Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Dzidowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-4415","authenticated-orcid":false,"given":"Danielle J","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2856-4525","authenticated-orcid":false,"given":"Amina","family":"Rhaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony","family":"Quintrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1031-1626","authenticated-orcid":false,"given":"Chun Hong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3907-304X","authenticated-orcid":false,"given":"Jacques E","family":"Raubenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2026.117299_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244944","article-title":"Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: a meta-analysis","volume":"16","author":"Bak","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.psychres.2026.117299_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.31128\/AJGP-08-20-5591","article-title":"Off-label medicine use: ethics, practice and future directions","volume":"50","author":"Bell","year":"2021","journal-title":"Aust. J. Gen. Pract."},{"key":"10.1016\/j.psychres.2026.117299_bib0003","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpsychires.2021.11.023","article-title":"Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality","volume":"149","author":"Berge","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2026.117299_bib0004","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/brainsci15030316","article-title":"Personal quality of life as an outcome measure of antipsychotic drug management of problem behaviours in adults with intellectual developmental disorders with or without autism spectrum disorder","volume":"15","author":"Bertelli","year":"2025","journal-title":"Brain Sci."},{"key":"10.1016\/j.psychres.2026.117299_bib0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10488-024-01408-9","article-title":"Metabolic monitoring for adults living with a serious mental illness on a second-generation antipsychotic agent: a scoping review","volume":"52","author":"Bui","year":"2025","journal-title":"Adm. Policy Ment. Health"},{"key":"10.1016\/j.psychres.2026.117299_bib0006","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.2174\/1381612821666150619092903","article-title":"Off-Label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends","volume":"21","author":"Carton","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.psychres.2026.117299_bib0007","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/aur.70047","article-title":"Relationship between antipsychotic use and cholesterol levels in a retrospective chart review of an adult autism clinic patient population","volume":"18","author":"Cejas","year":"2025","journal-title":"Autism. Res."},{"key":"10.1016\/j.psychres.2026.117299_bib0008","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/gps.2347","article-title":"Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study","volume":"25","author":"Chan","year":"2010","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1192\/bjp.bp.110.085670","article-title":"Safety of antipsychotics in people with intellectual disability","volume":"199","author":"Frighi","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/acps.13515","article-title":"Impact of low-dose quetiapine-use on glycosylated hemoglobin, triglyceride and cholesterol levels","volume":"147","author":"H\u00f8jlund","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2026.117299_bib0012","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcpt.13711","article-title":"Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: a nationwide cohort study","volume":"130","author":"H\u00f8jlund","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.psychres.2026.117299_bib0013","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1176\/appi.ps.202000381","article-title":"Factors associated with off-label utilization of second-generation antipsychotics among publicly insured adults","volume":"72","author":"Horvitz-Lennon","year":"2021","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.psychres.2026.117299_bib0014","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/cap.2009.0091","article-title":"Association between antipsychotics and body mass index when treating patients with tics","volume":"20","author":"Kompoliti","year":"2010","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117299_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0016","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/da.22489","article-title":"Risk of new onset type II DM in MDD patients receiving second-generation antipsychotics treatment: a nationwide cohort study","volume":"33","author":"Lin","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.psychres.2026.117299_bib0017","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-06","article-title":"Chapter 7: systematic reviews of etiology and risk (2020)","author":"Moola","year":"2024","journal-title":"JBI Manual Evid. Synth."},{"key":"10.1016\/j.psychres.2026.117299_bib0018","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00415-005-0830-z","article-title":"Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events: a controlled, open-label study","volume":"252","author":"Moretti","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.psychres.2026.117299_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2026.117299_bib0020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"The BMJ"},{"key":"10.1016\/j.psychres.2026.117299_bib0021","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/archinternmed.2012.28","article-title":"Antipsychotic use and myocardial infarction in older patients with treated dementia","volume":"172","author":"Pariente","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.psychres.2026.117299_bib0022","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/070674371205701202","article-title":"A Review of Pharmacoepidemiologic Studies of Antipsychotic Use in Children and Adolescents","volume":"57","author":"Patten","year":"2012","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0023","series-title":"Prospero Int. Regist","article-title":"Cardiometabolic adverse effects of long-term off-label antipsychotic treatment: a systematic review protocol","author":"Radha Krishnan","year":"2022"},{"key":"10.1016\/j.psychres.2026.117299_bib0024","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1007\/s00787-025-02771-0","article-title":"Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence","volume":"34","author":"Radha Krishnan","year":"2025","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/00048674231210209","article-title":"On- and off-label utilisation of antipsychotics in Australia (2000\u20132021): retrospective analysis of two medication datasets","volume":"58","author":"Radha Krishnan","year":"2023","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001666","article-title":"Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons","volume":"4","author":"Sahlberg","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.psychres.2026.117299_bib0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mdc3.12706","article-title":"Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: an Analysis from the Enroll-HD Database","volume":"6","author":"Schultz","year":"2019","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.psychres.2026.117299_bib0028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eurpsy.2007.07.005","article-title":"Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database","volume":"23","author":"Sicras-Mainar","year":"2008","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0029","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.psychres.2026.117299_bib0030","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2026.117299_bib0031","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41386-021-01163-7","article-title":"Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis","volume":"47","author":"Stogios","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2026.117299_bib0032","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","article-title":"Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials","volume":"79","author":"Taipale","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2026.117299_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19585969.2025.2449833","article-title":"Antipsychotic off-label use in the 21st century: an enduring public health concern","volume":"27","author":"Verdoux","year":"2025","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.psychres.2026.117299_bib0034","unstructured":"Wells, Shea B, O\u2019Connell D., Peterson J., Welch V., Losos M., Tugwell P., 2004. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses URL https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (accessed 2.26.24)."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126003598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126003598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:26:38Z","timestamp":1792052798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126003598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S0165178126003598"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117299","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term antipsychotic use and cardiometabolic adverse effects in adults with non-psychotic disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117299"}}